Navigation Links
Sangamo BioSciences Provides Update on Diabetic Neuropathy Clinical Programs
Date:6/6/2008

ly 30 subjects) was treated by intramuscular injection of 60 mg of SB-509 (30 mg of SB-509 per leg) into the lower limb and will be treated every 3 months. The remaining group (approximately 15 subjects) received an equal volume of placebo on the same schedule. Each subject will receive a total of two treatments (Day 0 and 90). Subjects receive injections in a distribution pattern that targets the major peripheral nerves in the legs and feet.

The expansion protocol will enroll approximately 45 additional subjects in the trial. Subjects will again be randomized to one of two groups in a 2:1 ratio. The larger group (approximately 30 subjects) will be treated by intramuscular injection of 60 mg of SB-509 (30 mg of SB-509 per leg) into the lower limb every 2 months. The remaining group (approximately 15 subjects) will receive an equal volume of placebo on the same schedule. Each subject will receive a total of three treatments (Day 0, 60 and 120). Subjects will receive injections in a similar pattern to that used in the initial part of the trial.

"In our Phase 1 studies we noted interesting clinical improvements in a number of subjects," said Edward Lanphier, Sangamo's president and CEO. "In addition to improvement in quantitative sensory testing (QST), three subjects with so-called "blocked nerves" or unmeasurable nerve conduction velocity measurements in the leg showed recovered and improved NCV after a single treatment with SB-509 and two of the three subjects showed recovery and improvement past a six-month follow-up period. As these observations were made in the Phase 1 trial, which studied only a small number of subjects, we initiated a Phase 2 trial, SB-509-701, to further investigate this finding. Our primary review of data from the SB-509-701 study continued to show a marked neurophysiologic improvement in severe diabetic neuropathy patients with unmeasurable nerve conduction velocities treated with SB-509. Based upon these observations we plan to
'/>"/>

SOURCE Sangamo BioSciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Sangamo BioSciences Announces Presentation of Data on ZFP Therapeutic for Glioblastoma at American Association for Cancer Research (AACR) Meeting
2. Sangamo BioSciences and Sigma-Aldrich Announce Publication of Study Demonstrating Zinc Finger Technology for Rapid Generation of Knock-Out Cell Lines
3. Sangamo BioSciences Reports 2007 Fourth Quarter and Year-End Financial Results
4. Sangamo BioSciences Announces Completion of Enrollment of Phase 2 Clinical Trial of ZFP Therapeutic for Diabetic Neuropathy
5. Sangamo BioSciences and Sigma-Aldrich Announce Nature Biotechnology Study Demonstrating Zinc Finger Technology for Modification of Human Stem Cells
6. Regado Biosciences Announces Publication in Circulation of Clinical Trial Results of REG1 Anticoagulation System
7. Magellan Biosciences Companies to Feature Automated Products and New Tests for MRSA at the American Society for Microbiology Meeting, Booth 743
8. Ardea Biosciences Presents Preclinical Data on RDEA119 Demonstrating Favorable Anti-Inflammatory Profile for Potential Use in Ulcerative Colitis
9. Ardea Biosciences Identifies Lead Development Candidate for Gout, RDEA594
10. Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results
11. Catalyst Biosciences Selects Drug Development Candidate in Factor VIIa Program for Hemophilia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... , July 25, 2014 /PRNewswire-iReach/ -- Dr. Michael Gabriel ... GPM Pediatrics, reacts to a recent study, which shows how ... Photo - http://photos.prnewswire.com/prnh/20140723/129709 According to ... severe stress are more likely than others to grow up ... pregnancy." There were two specific types of stress ...
(Date:7/24/2014)... , July 24, 2014  Parnell Pharmaceuticals Holdings ... that will be added to Parnell,s already extensive ... Pty Ltd, a biotechnology company. The compounds now ... shown promise in bone regeneration and dermal regeneration, ... the compounds for the veterinary market with the ...
(Date:7/24/2014)... Wis. , July 24, 2014  Restore ... specialty and compounded pharmaceuticals, announced that it is ... information unique to each individual based upon their ... possible by understanding the interaction between a patient,s ... "We,re very excited to provide this new ...
Breaking Medicine Technology:Dr. Michael Gabriel of GPM Pediatrics, a Noted Staten Island Pediatrics Clinic, Comments on Study, Which Names Grief as a Cause of Obesity in Children 2Parnell Acquires License for Intellectual Property and Rights to Develop Compounds for Bone and Dermal Regeneration 2Parnell Acquires License for Intellectual Property and Rights to Develop Compounds for Bone and Dermal Regeneration 3Parnell Acquires License for Intellectual Property and Rights to Develop Compounds for Bone and Dermal Regeneration 4Restore Health Launches Pharmacogenetic Testing, Enhancing Its Suite of Personalized Medicine Goods and Services 2Restore Health Launches Pharmacogenetic Testing, Enhancing Its Suite of Personalized Medicine Goods and Services 3
... Catalyst,Pharmaceutical Partners, Inc. (Nasdaq: CPRX ) ... sponsored by scientists at the U.S. Department of,Energy,s ... leads to rapid weight loss and reduced food ... 20, 2008 in the journal Synapse, a,prestigious peer-reviewed ...
... MONTREAL, Aug. 20 Enobia Pharma, an emerging ... bone,disorders, today announced that the first patient in ... is investigating Enzyme,Replacement Therapy (ERT) with ENB-0040 for ... bone disorder for which there is no approved,treatment., ...
Cached Medicine Technology:Catalyst Pharmaceutical Partners Announces Publication of Animal Data Demonstrating Vigabatrin Effective for Weight Loss 2Catalyst Pharmaceutical Partners Announces Publication of Animal Data Demonstrating Vigabatrin Effective for Weight Loss 3Enobia Pharma Initiates Clinical Testing of Enzyme Replacement Therapy to Treat Hypophosphatasia 2Enobia Pharma Initiates Clinical Testing of Enzyme Replacement Therapy to Treat Hypophosphatasia 3
(Date:7/26/2014)... 2014 The European Artificial lift market report ... analysis and forecast of revenue. The artificial lift market in ... 2013 to around $5.4 billion by 2018, at a CAGR ... the TOC of European artificial lift market report, to get ... glimpse of the segmentation in European Artificial lift market, and ...
(Date:7/26/2014)... Recently, iFitDress.com, a popular supplier of wedding dresses and ... range of high quality party outfits. Additionally, it has ... they are now provided at discounted prices, up to ... the leading suppliers in the international market. According to ... dresses have flattering looks and fine craftsmanship. They ...
(Date:7/26/2014)... News) -- Pools can provide much-needed relief from the ... they swallow too much chlorinated water, experts warn. ... ones to get water in their mouth. Some kids ... warnings from their parents. Although swallowing a small ... parents to realize that ingesting too much can lead ...
(Date:7/26/2014)... 2014 As reported by Lauren ... based on 3 factors: smaller spaces, multi-generational access, and ... trend of 2014 lists, including this article on ... Amerec , a leading manufacturer of steam bath generators, ... due to smaller spaces and an effort to reduce ...
(Date:7/26/2014)... New York, NY (PRWEB) July 26, 2014 ... by Infosecurity magazine on July 23rd, new research by ... are starting to rewrite their playbook, now focusing more ... individuals en masse who have become increasingly wise to ... (GDF) founder and CEO/CTO, Joe Caruso, talks about ...
Breaking Medicine News(10 mins):Health News:Europe Artificial Lift Services Market is Expected to Reach $5.4 Billion in 2018 - New Report by MicroMarket Monitor 2Health News:Europe Artificial Lift Services Market is Expected to Reach $5.4 Billion in 2018 - New Report by MicroMarket Monitor 3Health News:Europe Artificial Lift Services Market is Expected to Reach $5.4 Billion in 2018 - New Report by MicroMarket Monitor 4Health News:Europe Artificial Lift Services Market is Expected to Reach $5.4 Billion in 2018 - New Report by MicroMarket Monitor 5Health News:High Quality Wholesale Party Dresses Online at iFitDress.com 2Health News:Don't Let Kids Drink Pool Water 2Health News:Amerec Finds Bathroom Design Trends Change Based on Water Consumption and Other Factors 2Health News:Businesses the New Target for Nigeria’s 419 Cyber-Scammers 2Health News:Businesses the New Target for Nigeria’s 419 Cyber-Scammers 3Health News:Businesses the New Target for Nigeria’s 419 Cyber-Scammers 4Health News:Businesses the New Target for Nigeria’s 419 Cyber-Scammers 5Health News:Businesses the New Target for Nigeria’s 419 Cyber-Scammers 6
... April 3 /PRNewswire-FirstCall/ - NUCRYST Pharmaceuticals,Corp. (NASDAQ: NCST ... will,step down as Vice President Finance & Administration and ... another company in a field,unrelated to any of NUCRYST,s ... search for Mr. Lurier,s successor., "On behalf of ...
... April 3 /PRNewswire-FirstCall/ - SXC Health Solutions, Corp.,("SXC" or ... leading provider of,pharmacy benefits management services, announces that Mark ... CFO, will present at the,SunTrust 37th Annual Institutional Conference ... place on Tuesday, April 15,2008 at 9:40 am Eastern ...
... FRANCISCO, Calif., April 3, 2008 ,Renovis, Inc. (Nasdaq: ... the,discovery and development of drugs for major medical ... announced today that the waiting,period under the Hart-Scott-Rodino ... without the United States Federal Trade Commission,requesting additional ...
... 2008 Medical Records Institute (MRI),announces a new ... will be announced at the TEPR 2008 opening ... This new TEPR Award is the first ... their products meet a range of EMR medicolegal,requirements, ...
... half just occasionally had too much , , THURSDAY, April 3 ... are habitual drinkers, but new research suggests that people who ... who drive while intoxicated. , When it comes to drunk ... said study author Dr. Nicole T. Flowers, a medical epidemiologist ...
... Lubbock, TX April 3, 2008 Patients with genital ... served by healthcare providers who initiate positive discussions about them, ... Womens Health. , Yet, too often, such discussions ... related to the piercings, due to healthcare providers uneasiness over ...
Cached Medicine News:Health News:NUCRYST Announces Senior Management Change 2Health News:NUCRYST Announces Senior Management Change 3Health News:Renovis Announces Expiration of Hart-Scott-Rodino (HSR) 30-Day Waiting Period; Merger With Evotec on Track to Close in Early May, 2008 2Health News:Renovis Announces Expiration of Hart-Scott-Rodino (HSR) 30-Day Waiting Period; Merger With Evotec on Track to Close in Early May, 2008 3Health News:Renovis Announces Expiration of Hart-Scott-Rodino (HSR) 30-Day Waiting Period; Merger With Evotec on Track to Close in Early May, 2008 4Health News:Medical Records Institute Announces New TEPR Award for EMRs Best Meeting Medicolegal Requirements 2Health News:Alcoholics Not to Blame for All Drunk Driving Cases 2
... Radiopaque Bone Cement consists of ... sterile,ampule containing bone cement liquid ... a sterile polyethylene bag,containing bone ... pouch. The interiors of the ...
... ORTHOSET Radiopaque Bone Cement consists ... a sterile,ampule containing bone cement ... and a sterile polyethylene bag,containing ... peelable pouch. The interiors of ...
A "doughy" type of bone cement intended for manual application....
... technology, such as a recessed scratch-resistant sapphire ... housings, this arthroscope has superior clarity and ... Steris and steam autoclaving or soaked in ... to fit ACMI, Wolf, Dyonics and Storz ...
Medicine Products: